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INVESTIGATING THE FUNCTIONS OF PGC-1 ISOFORMS IN RETINAL 
PIGMENT EPITHELIA METABOLISM AND THEIR IMPLICATIONS ON AGE-




Retinal Pigment Epithelia (RPE) degeneration is a key event in the development 
of age-related macular degeneration (AMD). RPE dysfunction in AMD is thought 
to occur through the accumulation of reactive oxygen species (ROS) and 
oxidative damage. The transcriptional co-activators, PGC-1α and PGC-1β, are 
important regulators of mitochondrial biogenesis and anti-oxidant capacity. Our 
group has previously shown that the PGC-1α protein promotes RPE oxidative 
metabolism and that overexpression of the PGC-1α gene protects cells from 
AMD-associated pro-oxidants. On the other hand, PGC-1β gene expression has 
been found to be upregulated in patients with neovascular AMD, and in-vitro 
overexpression of PGC-1β damages cells and induces pro-oxidant conditions.  
 
OBJECTIVE: 
Given the divergence of PGC-1α and PGC-1β functions in RPE and their clinical 
relevance in AMD pathogenesis, this project will seek to investigate the impact of 
the upregulation of PGC-1α and PGC-1β in RPE metabolism. PGC-1α will be 
upregulated through treatment with compound ZLN005. A new methodology for 
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In-vitro experiments were performed on the ARPE-19 cell line. Cells were treated 
with 10µM of ZLN005 for 24 hours. Oxidative stress was induced by exposure to 
H2O2 and NaIO3 under serum-free conditions. Lactate dehydrogenase (LDH) 
levels were used to quantify cell death. Quantitative PCR (qPCR) and Western 
Blot were performed to measure changes in gene and protein expression 
respectively. Superoxide production by the mitochondria was measured to 
evaluate ROS levels within the cell. Intravitreal injections of 20µM ZLN005 were 
performed on eight-week old male C57BL/6J mice. After 24 and 72 hours of 
treatment, the mice were euthanized and the enucleated eyes were dissected to 
obtain the RPE and neural retina layers. Total RNA was extracted from these 
layers and qPCR was performed to measure gene expression. A tetracycline-
inducible PGC-1β plasmid was designed and transfected into ARPE-19 cells. 
The cells were exposed to 0.01-100µg/ml doxycycline for 48-hours and qPCR 
was used to measure gene expression. Transfected cells were treated with 







Gene expression analysis on ARPE-19 cells treated with ZLN005 showed robust 
upregulation of PGC-1a, PGC-1β and their associated transcription factors and 
enzymes. Induction of PGC-1a at the protein level was also confirmed. ZLN005 
efficiently protected ARPE-19 cells from H2O2 and NaIO3 cytotoxicity and its 
protection was negated in PGC1a-silenced cells. Treatment with ZLN005 also 
decreased mitochondrial superoxide production. ZLN005 intravitreal injections 
were safely administered to the animals and did not cause cataracts or other 
damage to the ocular tissues. While statistical significance in gene expression 
changes was limited due to the small sample size, anti-oxidants GPX1 and 
TXN2, and electron transport chain gene, ATP50, were found to be potentially 
induced in the neuro-retina, while FOXO3 was found to be downregulated. 
Evaluation of our novel tetracycline-inducible PGC-1β adenoviral vector showed 
that upregulation of PGC-1β was efficiently controlled by the addition of 
doxycycline to transfected cells. Upon exposure to H2O2, transfected cells treated 
with doxycycline experienced greater cell death than transfected cells not 
exposed to doxycycline. ZLN005 treatment was able to decrease cell death in 
both conditions.  
 
CONCLUSION: 
The present study shows that ZLN005 efficiently protects RPE cells from 
oxidative damage through selective induction of PGC-1a. While still preliminary, 
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the in-vivo study indicates that ZLN005 is safe to be injected into the eye and 
may be able to increase the expression of mito-protective and anti-oxidant genes 
in the neuronal retina. In addition, our design of the tetracycline inducible PGC-
1β plasmid allows for tight control over PGC-1β expression through doxycycline 
addition. Upregulation of PGC-1β at levels similar to those observed in clinical 
conditions caused increased pro-oxidant induced cell death and treatment with 









READER APPROVAL PAGE………………………………………………………….iii 
ACKNOWLEDGMENTS ....................................................................................... iv 
ABSTRACT ........................................................................................................... v 
TABLE OF CONTENTS ....................................................................................... ix 
LIST OF TABLES ................................................................................................. xi 
LIST OF FIGURES .............................................................................................. xii 
LIST OF ABBREVIATIONS ................................................................................ xiii 
INTRODUCTION ...................................................................................................1 
Characterization of Age-Related Macular Degeneration ...................................1 
Retinal Pigment Epithelia dysfunction is integral for AMD development ............4 
PGC-1α and PGC-1β play divergent roles in RPE function ...............................7 
Specific Aims ...................................................................................................10 
METHODS ..........................................................................................................11 
Cell culture.......................................................................................................11 
RNA collection and quantitative PCR ..............................................................11 
Protein Collection and Western Blot Analysis ..................................................14 
 
 x 
Quantification of mitochondria superoxide production .....................................15 
Cell Death Assay .............................................................................................16 
Animal Study ...................................................................................................17 
Design of PGC-1β Tetracycline Inducible (Tet-On) Adenovirus.......................17 
Transfection of ARPE-19 cells with PGC-1β Tet-On plasmid ..........................18 
Statistical Analysis ...........................................................................................19 
RESULTS ...........................................................................................................20 
ZLN005 upregulates PGC-1α and its associated targets in ARPE-19 cells .....20 
ZLN005 anti-oxidant effect on RPE is PGC-1α-dependent ..............................23 
ZLN005 increases expression of certain anti-oxidants in the neural retina ......26 









LIST OF TABLES 
 
 
Table Title Page 
1 Sequence of primers used for qPCR 12 - 14 
   
   
   
   










Figure Title Page 
1 Stages of AMD observed at the fundus of the eye 
during ophthalmic examination, as proposed by the 
Age-Related Eye Disease Study (AREDS). 
1 
2 Main forms of advanced AMD, geographic atrophy 
(dry AMD) versus neovascularization (wet AMD). 
3 
3 Location of the RPE.  4 
4 PGC-1β Tetracycline Inducible (Tet-On) Plasmid. 18 
5 ZLN005 upregulates PGC-1α in ARPE-19 cells. 22 
6 ZLN005 protects ARPE-19 cells from pro-oxidant 
induced cell death through the upregulation of PGC-
1α. 
25 
7 ZLN005 increases expression of anti-oxidants in the 
neural retina. 
27 









LIST OF ABBREVIATIONS 
 
AMD ................................................................ Age-Related Macular Degeneration 
AmpR .................................................................................... Ampicillin Resistance 
AREDS ................................................................. Age-Related Eye Disease Study 
ATCC ................................................................ American Type Culture Collection 
BCA ................................................................................. Bicinchoninic Acid Assay 
CAT ........................................................................................................... Catalase 
cDNA ...........................................................Complimentary Deoxyribonucleic Acid 
CNV ......................................................................... Choroidal Neovascularization 
DMEM/F12 ........ Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 media 
DMSO ....................................................................................... Dimethyl Sulfoxide 
Dox ....................................................................................................... Doxycycline 
EGFP ............................................................. Enhanced Green Florescent Protein 
ESRRA .............................................................. Estrogen Related Receptor Alpha 
FBS ......................................................................................... Fetal Bovine Serum 
GPX ...................................................................................Glutathione Peroxidase 
HBSS ....................................................................... Hank’s Buffered Salt Solution 
HRP ..................................................................................Horseradish Peroxidase 
IgG ............................................................................................. Immunoglobulin G 
IRES ................................................................ Internal Ribosome Entry Sequence 
LDH ................................................................................... Lactate Dehydrogenase 
Mt ...................................................................................................... Mitochondrial 
 
 xiv 
NF-kB ................... Nuclear Factor kappa-light-chain-enhancer of activated B cells 
NRF .............................................................................. Nuclear Respiratory Factor 
OD ................................................................................................... Optical Density 
ox-LDL ............................................................... Oxidized Low Density Lipoprotein 
PBS-T ........................................ Phospho-Buffed Saline, 0.1% (vol/vol) Tween-20 
PenStrep .............................................................................Penicillin-Streptomycin 
PEDF .............................................................. Pigment Epithelium-Derived Factor 
PGC-1α .... Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
PGC-1β ...... Peroxisome proliferator-activated receptor gamma coactivator 1-beta 
PIGF ..................................................................... Placenta Derived Growth Factor 
PMSF ................................................................... Phenylmethanesulfonyl Fluoride 
POS ...................................................................... Photoreceptor Outer Segments 
qPCR ..................................................... Quantitative Polymerase Chain Reaction 
RNA ............................................................................................. Ribonucleic Acid 
ROS ............................................................................... Reactive Oxygen Species 
RPE ................................................................................. Retinal Pigment Epithelia 
SOD .................................................................................... Superoxide Dismutase 
TBS-T ................................................. Tris-Buffed Saline, 0.1% (vol/vol) Tween-20 
TK ............................................................................................................. Total Kill 
THBS1 ...................................................................................... Thrombospondin-1  
VEGF ..............................................................Vascular Endothelial Growth Factor 





Characterization of Age-Related Macular Degeneration 
Age-Related Macular Degeneration (AMD) is a multifactorial degenerative 
disease of the retina, retinal pigment epithelia (RPE), Bruch’s membrane, and 
choroidal capillaries in the central, posterior region of the eye called the macula 
(Fig. 1A, 1B). Damage to the macula is largely responsible for the loss of photopic 
vision and visual acuity in AMD patients (Hageman et al. 1995). Affecting 8.7% of 
the world (Wong et al. 2014), AMD is the third leading cause of vision loss in the 
geriatric population (Resnikoff et al. 2004). By 2020, AMD is projected to impact 
196 million individuals globally (Wong et al. 2014). Risk factors of AMD include 
age (Klein, Klein, and Linton 1992; Mitchell et al. 2002; Jonasson et al. 2014; 
Figure 1: Stages of AMD observed at the fundus of the eye during ophthalmic 
examination, as proposed by the Age-Related Eye Disease Study (AREDS) (A) 
Anatomy of the eye: the red box indicates the macula, which is an area on the 
posterior retina rich in photoreceptors (National Eye Institute 2018). The center of the 
macula is called the fovea. (B)-(F) Funduscopic images of (B) Normal Eye: the circle 
marks the macula of the eye. (C) Early AMD: the arrow points to the presence of 
medium sized (63-123 µm) drusen. (D) Intermediate AMD: the arrow points to the 
presence of a large druse (greater than 124 µm) and many medium drusen. (E) 
Geographic Atrophy (Non-neovascular Advanced AMD): the arrow points to the 
presence of soft confluent drusen. (F) Neovascular Advanced AMD: the white arrow 
shows choroidal neovascularization and the blue arrow shows sub-retinal 




















Yasuda et al. 2009; Evans 2001), smoking (Smith et al. 2001; Klein et al. 2008; 
Thornton et al. 2005; Christen 1996; Chakravarthy et al. 2007), and genetic 
variants (Seddon, Ajani, and Mitchell 1997; Weeks et al. 2004; Despriet et al. 2006; 
Jabbarpoor Bonyadi et al. 2017). (National Eye Instit ute 2 018 )(J age r, Mi eler,  an d Mille r 20 08)  
Another important risk factor for AMD is the presence of drusen. Drusen 
are debris-like extracellular deposits that aggregate with age between the RPE 
and the Bruch’s membrane in the peripheral retina. The accumulation of drusen 
in the macula is a major risk factor and bio-indicator for AMD. Drusen can be 
observed as yellow lesions in the funduscopic examination of the eye and is 
characterized by size, margin and number.  This characterization of drusen is an 
important measure in the staging of AMD as seen in Figure 1. There are many 
different methods for staging AMD (Bird et al. 1995; Klein et al. 1991; Age-
Related Eye Disease Study Research Group 2001), but the method defined by 
the Age-Related Eye Disease Study Research group (AREDS) is most 
commonly used. AREDS categorizes AMD into four levels, with Level 1 
describing features in a normal eye (Fig. 1B, Fig. 2A). Level 2 or early AMD (Fig. 
1C) is characterized by changes in RPE pigmentation and the presence of 
medium sized drusen. Excessive drusen accumulation and further RPE 
dysfunction can cause the disease to progress to Level 4 or advanced AMD (Fig. 
1E and 1F), which can present as non-neovascular/dry AMD or neovascular/wet 
AMD. Dry AMD (Fig. 2B) is characterized by the geographic atrophy of 




vision. Wet AMD (Fig. 2C) is the aberrant growth of choroidal blood vessels in 
the retina, called choroidal neovascularization (CNV), and leads to sudden and 
significant vision loss due to sub-retinal edema and hemorrhage.   
Dry AMD, which affects 90% of AMD patients, currently has no 
established effective treatment. For wet AMD, anti-vascular endothelial growth 
factor (anti-VEGF) agents are the main therapeutics used to manage CNV (Rein 
2009). While effective, sustained use of anti-VEGF agents can lead to adverse 
local and systemic side effects, such as retinal atrophy and systemic thrombotic 
complications (Ventrice et al. 2013). Alternatives such as anti-oxidant 
A. Normal Retina  B. Dry AMD C. Wet AMD 
Figure 2: Main forms of advanced AMD, geographic atrophy (dry AMD) versus 
neovascularization (wet AMD). (A) The normal retina consists of ganglion cells, 
bipolar cells, horizontal cells, and photoreceptors. The RPE, Bruch’s membrane and 
the choroidal blood supply lie below the neural retina. The microglial cell migrates 
around the retina as denoted by the dashed line. (B) In dry AMD, geographic atrophy 
of the RPE and overlying photoreceptors occurs. In addition, the Bruch’s membrane 
thickens and the choroidal vasculature constricts. These changes lead to the gradual 
loss of central vision. (C) Wet AMD is characterized by the growth of new leaky blood 
vessels through breaks in the Bruch’s membrane, also known as choroidal 
neovascularization (CNV). The leaky vessels cause edema in the sub-retinal space 
and can hemorrhage in the retina, releasing systemic macrophages into the immune 
privileged eye and causing sudden and extreme vision loss. The arrow between dry 
and wet AMD indicates that one form can progress into the other (Ambati, Atkinson, 




supplements (Rein 2009) and photodynamic therapy (for the V. S. Group et al. 
1999; Arnold et al. 2001) help decrease the rate of disease progression (Bressler 
et al. 2003), but they tend to be less efficacious and pose their own unfavorable 
effects (Olli P. Heinonen and Demetrius Albanes 1994; Eva Lonn, MD 2005), 
such as causing an increased risk of lung cancer. Therefore, there exists a need 
for a better understanding of the biochemical pathways involved in the 
development and progression of AMD in order to innovate new pharmacological 
therapies to manage, and potentially cure, AMD. 
  (Ambati, Atki nson , an d Gelf and  20 13) 
 
Retinal Pigment Epithelia dysfunction is integral for AMD development 
 The RPE is a polarized monolayer of cells that is integral for the survival of 
photoreceptors and the function of the eye. As seen in Figure 3, microvilli on the 
apical surface of the RPE surround the photoreceptor outer segments (POS) in 
the retina, while the basal surface sits on a specialized membrane (called the 
Figure 3: Location of the RPE (A) Light micrograph of the RPE, choroid (above) 
and photoreceptors (below) in a human eye  (B) Corresponding carton depiction of 
the structures viewed in the light micrograph CC: choriocapillaries, BM: Bruch’s 
Membrane, RPE: Retinal Pigment Epithelium, ap: apical microvilli processes, os: 






Bruch’s membrane) and is in close contact with the choroidal vasculature, the 
main blood supply of the photoreceptors.  The RPE plays an important role in 
shuttling ions, metabolites and macromolecules between the blood and retina 
(Miller and Edelman 1990; Quinn et al. 1992) and maintains the composition of 
the sub-retinal space (Adijanto et al. 2009; deS Senanayake P et al. 2001). In 
addition, the tight junctions and complex junctional attachments in the RPE help 
prevent passive diffusion of substances from the fenestrated choroidal capillaries 
to the retina (Rizzolo et al. 2011), thereby forming the outer blood-retinal barrier 
by separating the retina from the rich blood supply in the choroid.   
The RPE also directly participates in photo transduction by regenerating 
the 11-cis-retinal chromophore (Fongs et al. 1984; Bridges 1976) responsible for 
the light sensitivity of the photoreceptors. Apically located melanosomes in the 
RPE aid in absorbing scattered light thereby preventing reflections within the eye. 
Since the eye is an immune privileged space, the RPE is responsible for 
secreting immunosuppressive factors (Taylor, Dixit, and Yu 2015) and carrying 
out phagocytosis of POS that have undergone photo-oxidative damage (Chiang 
et al. 2017; Young and Bok 1969). The RPE also secretes growth and 
neurotrophic factors, such as VEGF and pigment epithelium-derived 
factor (PEDF), to maintain stability of the surrounding vascular and neuronal 
tissues (Adamis et al. 1993). 
Because of its location between the rich oxygen supply in the choroid and 




reactive oxygen species (ROS). Further ROS is generated by the electron 
transport chain (ETC) in respiration and during phagocytosis of POS (Miceli, 
Liles, and Newsome 1994). To protect themselves from oxidative stress, the RPE 
employ two separate mechanisms. The first is the use of melanosomes and other 
light absorbing pigments to uptake excess energy. The second mechanism is the 
use of anti-oxidant enzymes, such as superoxide dismutase (SOD1, SOD2), 
catalase (CAT), and glutathione peroxidase (GPX) (Lu et al. 2009; Zou et al. 
2012), and small molecules, such as glutathione. Both are controlled by the 
nuclear respiratory factor 2 (NRF2 or NRE2L2) transcription factor (Plafker, 
O’Mealey, and Szweda 2012; Iacovelli et al. 2016).  
With age, this balance between ROS generation and removal can be 
disrupted. Auto-fluorescent granules, called lipofuscin, are a byproduct of 
photoreceptor phagocytosis and begin occupying large volumes in the RPE with 
age. Irradiation of lipofuscin deposits break down its bisretinoid, lipid, and protein 
components causing photo-oxidative damage to the RPE (Wassell et al. 1999; 
Rózanowska et al. 1995; Boulton et al. 1993). The age-related loss of anti-
oxidant enzymes decrease the RPE’s defense against oxidative stress (Frank, 
Amin, and Puklin 1999). This loss plays a significant role in AMD pathogenesis 
as animal models with anti-oxidant enzyme knock-outs have shown development 
of several AMD features (Justilien et al. 2007; Mao et al. 2014; Zhao et al. 2011). 
Smoking, a major AMD risk factor, induces further oxidative stress through the 




stress causes mitochondrial damage (Karunadharma et al. 2010; H. Lin et al. 
2011; Feher et al. 2006) which leads to significant RPE dysfunction, inducing 
pathological secretion of growth factors promoting CNV or cell death and 
geographic atrophy.  
This increase in oxidative stress also dysregulates lipid metabolism, 
causing the production of oxidized low-density lipoproteins (ox-LDL). Oxidized 
LDL can be produced during phagocytosis of POS (Picard et al. 2010; Huang, 
Curcio, and Johnson 2008; Holz et al. 1994) or obtained exogenously from the 
blood through the CD36 receptor in RPE (Yin et al. 2012; Picard et al. 2010). 
Once inside the cell, ox-LDL is sequestered in lysosomes, and causes 
dysregulation of the phagocytosis function of the RPE and buildup of lipofuscin 
(Gnanaguru et al. 2016; Hoppe et al. 2004). In addition, ox-LDL has been found 
to activate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) 
(Ebrahimi et al. 2014; Stewart et al. 2010; Joffre et al. 2007; Hu et al. 2014; 
Larrayoz et al. 2010; Rodriguez, Alam, and Lee 2004; Dasari et al. 2010), which 
has been shown to play a role in neovascularization of the retina (Yoshida et al. 
1999).  
 
PGC-1α and PGC-1β play divergent roles in RPE function 
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α) and beta (PGC-1β) are transcriptional co-activators that regulate 




al. 1999; Puigserver et al. 1998), including the retina (Saint-Geniez et al. 2013; 
Guo et al. 2014; Egger et al. 2012). To mediate their functions, the PGC-1 
isoforms interact with transcription factors, such as estrogen- related receptor 
alpha (ESRRA)(Mootha et al. 2004) and nuclear respiratory factor 1 and 2 (NRF1 
and NRF2)(Wu et al. 1999) to control respiration, mitochondrial biogenesis, and 
expression of anti-oxidants (Iacovelli et al. 2016).  
While PGC-1α and PGC-1β share numerous gene targets and have 
sequence homology (J. Lin et al. 2002), they can carry out different functions in a 
tissue-specific manner. For instance, in brown adipose tissue, PGC-1α promotes 
thermogenesis (Puigserver et al. 1998) and PGC-1β is involved in energy 
expenditure (Kamei et al. 2003). In the RPE, epithelial maturation is correlated 
with PGC-1α upregulation and PGC-1β repression (Iacovelli et al. 2016). Over-
expression of PGC-1α in RPE was also found to downregulate PGC-1β 
expression. Therefore, there is a need to elucidate the specific functions of both 
genes in the RPE.  
So far, PGC-1α has been found to regulate expression of VEGF, control 
phagocytic and lysosomal function, enhance respiration and mitochondrial 
biogenesis, upregulate anti-oxidant genes in the RPE, and protect RPE from 
oxidative stress (Saint-Geniez et al. 2013; Iacovelli et al. 2016; Roggia and Ueta 
2015). Due to its impact on oxidative stress, PGC-1α is being investigated as a 
therapeutic for numerous degenerative diseases, including AMD. A novel 




in skeletal muscle (Zhang et al. 2013). Since ZLN005’s effects in RPE have not 
been evaluated, this project will focus on examining the impact of ZLN005 on 
RPE function and metabolism in-vitro and evaluating its therapeutic efficiency in 
a mouse model of acute RPE oxidative damage.  
Meanwhile, the function of PGC-1β in RPE metabolism and homeostasis 
remains unclear. Preliminary data from our group has shown that forced 
expression of PGC-1β increases mitochondrial respiration like PGC-1α, but 
downregulates the expression of anti-oxidant genes, causing increased RPE cell 
death in basal and pro-oxidative conditions (Charles and Saint-Geniez 2017). In 
ARPE-19 cells, PGC-1β levels are upregulated upon exposure to ox-LDL, a 
pathological lipoprotein that is present in the RPE and drusen.  Clinical data has 
shown a significant increase in PGC-1β (> 2-fold), but not PGC-1α, expression in 
the RPE/choroid layer of patients with advanced neovascular AMD compared to 
age-matched controls and intermediate AMD subjects (Courtesy of Dr. Margaret 
DeAngelis, John A. Moran Eye Center, Salt Lake City, UT). Given PGC-1β 
upregulation in neovascular AMD, the effect of PGC-1β on angiogenic factors 
was tested in-vitro. PGC-1β upregulation was found to induce expression of 
Placenta-derived Growth Factor (PlGF), a potent pro-angiogenic factor, while 
decreasing the expression of anti-angiogenic factors, such as thrombospondin-1 
(THBS1) and PEDF. All together, these findings strongly suggest that 
pathological induction of PGC-1β in RPE cells may participate in AMD 




neovascularization. However, it is important to note that the adenovirus-based 
PGC-1β augmentation method used led to high and uncontrolled overexpression 
of the gene in RPE, potentially triggering aberrant cellular responses. Therefore, 
functional analysis with a tightly controlled expression system should be 
performed to address this issue and confirm the deleterious functions of PGC-1β 
in RPE cells.  
 
Specific Aims 
Given the divergence of PGC-1α and PGC-1β functions in RPE and their clinical 
relevance in AMD pathogenesis, this project will seek to investigate the impact of 
the upregulation of PGC-1α and PGC-1β in RPE metabolism. The specific aims 
of the project are: 
1. To investigate the protective effects of compound ZLN005, a selective 
PGC-1α up-regulator, on RPE gene expression and susceptibility to 
oxidative stress. 
2. To develop a new methodology for controlled PGC-1β expression in RPE 
and to analyze the effect of physiological PGC-1β induction in RPE 







The human retinal pigment epithelia ARPE-19 cell line was obtained from 
the American Type Culture Collection (ATCC, Manassas, VA). ARPE-19 cells 
were expanded in growth medium, consisting of Dulbecco's Modified Eagle 
Medium: Nutrient Mixture F-12 media (DMEM/F12, Thermo Fisher Scientific, 
Wilmington, DE, USA) supplemented with 10% Fetal Bovine Serum (FBS, 
Atlanta Biologicals, Lawrenceville, GA), and 1% penicillin and streptomycin 
(PenStrep, Lonza, Walkersville, MD, USA), at 37°C and 10% CO2. Once cells 
reached confluency, they were maintained in differentiation medium consisting of 
DMEM/F12, 1% FBS and 1% PenStrep. Unless otherwise specified, quiescent 
ARPE-19 cells were grown to confluency in growth medium and then maintained 
for 24 hours in differentiation medium. For all experiments involving differentiated 
ARPE-19, cells were grown to confluency and then maintained in differentiation 
medium for one week before further treatment. 
 
RNA collection and quantitative PCR 
 Cells were maintained in serum free conditions for 24 hours and then 
treated for 48 hours with 10µM ZLN005 (Cayman Chemicals, Ann Arbor, MI, 
USA) or a similar dilution of dimethyl sulfoxide (DMSO, D8418-Sigma, St.Louis, 
MO, USA) vehicle (veh), prepared in serum free DMEM/F12. Total RNA was 




distilled water. The concentration and purity of each sample was measured using 
the NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific).  
Reverse transcription was performed with 1μg of RNA to produce the 
associated complimentary DNA (cDNA) using the IV Vilo Mastermix with 
EZDNASE (Thermo Fisher Scientific). To measure the changes in gene 
expression, a quantitative polymerase chain reaction (qPCR) was performed 
using 3 μl of cDNA template, the Fast Universal SYBR Green Master Mix, and 
the Lightcycler 480 (Roche Life Sciences, Indianapolis, IN, USA). Data was 
normalized to the mean expression of housekeeping genes (CRYAB, PPIH, b-
ACTIN, and HPRT1 for the human ARPE-19 cell line, PPIA, B2M, and HPRT1 for 
the in-vivo mouse retina and RPE/choroid) and quantified using the 
2−ΔΔCT method. The primer sequences used are listed in Table 1 below. 
 
Gene Code Gene Name Primer Sequence 
qhCRYAB Human Crystallin Alpha B 
Forward (5'-3') GTTCTTCGGAGAGCACCTGTT 





Forward (5'-3') CCCCAACAATAAGCCCAAG 






Forward (5'-3') CCTGGCGTCGTGATTAGTGAT 
Reverse (5'-3') AGACGTTCAGTCCTGTCCATAA 
qhβactin Human Beta-Actin 
Forward (5'-3') CTGTCTGGCGGCACCACCAT 






Coactivator 1 Alpha 
Forward (5'-3') GTCACCACCCAAATCCTTAT 
Reverse (5'-3') ATCTACTGCCTGGAGACCTT 










Forward (5'-3') CCACATCCTACCCAACATCAAG 





Forward (5'-3') TATGGTGTGGCATCCTGTG 





Forward (5'-3') TCCAGTCAGAAACCAGTGGAT 
Reverse (5'-3') GAATGTCTGCGCCAAAAGCTG 
qhFOXO3 Human Forkhead box O3 
Forward (5'-3') CTTCAAGGATAAGGGCGACA 





Forward (5'-3') TTTGAATCCCTATGTGAAGCGTT 
Reverse (5'-3') CCTTGGGTATTGCTTAATCGACC 
qhSOD2 Human Superoxide Dismutase 2 
Forward (5'-3') CAGACCTGCCTTACGACTATGG 
Reverse (5'-3') CGTTCAGGTTGTTCACGTAGG 
qhFIS1 Human Fission, Mitochondrial 1 
Forward (5'-3') TGACATCCGTAAAGGCATCG 
Reverse (5'-3') CTTCTCGTATTCCTTGAGCCG 
qhMFN1 Human Mitofusin 1 
Forward (5'-3') TGCCCTTCACATGGACAAAG 
Reverse (5'-3') CTCTGTAGTGACATCTGTGCC 
eGFP Enhanced Green Fluorescent Protein 
Forward (5'-3') AAGCAGCACGACTTCTTCAAGTC 





Forward (5'-3') GAGCTGTTTGCAGACAAAGTTC 






Forward (5'-3') TCAGTCAACGGGGGACATAAA 
Reverse (5'-3') GGGGCTGTACTGCTTAACCAG 
qmB2M Mouse Beta-2-Microglobulin 
Forward (5'-3') TTCTGGTGCTTGTCTCACTGA 






Coactivator 1 Alpha 
Forward (5'-3') AGCCGTGACCACTGACAACGAG 















Forward (5'-3') GGAGGACGGCAGAAGTACAAA 
Reverse (5'-3') GCGACACCAGAGCGTTCAC 
qmFOXO3 Mouse Forkhead box O3 
Forward (5'-3') AGTGGATGGTGCGCTGTGT 





Forward (5'-3') GACAAGATCATCAACCTGCCTGTAG 





Forward (5'-3') CACCGAGATGAACGATCTG 
Reverse (5'-3') CAGGTCGGACGTACTTGAG 
qmTXN2 Mouse Thioredoxin 2 
Forward (5'-3') CACACAGACCTTGCCATTGA 





Forward (5'-3') AGGCCCTTTGCCAAGCTT 
Reverse (5'-3') TTCTCCTTAGATGCAGCAGAGTACA 
 
 
Protein Collection and Western Blot Analysis 
Prior to 48-hour treatment with 10µM ZLN005 or vehicle, the cells were 
kept in serum free conditions for 24 hours. The vehicle and 10µM ZLN005 were 
prepared in serum free DMEM/F12. Protein lysates were collected on ice using 
1× Cell Lysis Buffer (Cell Signaling, Danvers, MA, USA) containing 2 mM 
phenylmethanesulfonyl fluoride (PMSF), sonicated and then quantified using the 
bicinchoninic acid assay (BCA) method (Thermo Scientific Pierce, Rockford, IL, 
USA). Electrophoresis was carried out on 10% Mini-PROTEAN® TGX gels (Bio-
Rad Laboratories, Hercules, CA) using 80μg of protein and transferred to 
Immobilon-FL polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, 
USA).  Dilutions of primary antibodies were made in 5% non-fat dry milk 




Buffed Saline, 0.1% (vol/vol) Tween-20 (TBS-T). The concentrations of primary 
antibodies used were: mouse anti-human PGC-1α –1:250 in 5% milk PBS-T, 
mouse anti-human α-tubulin – 1:1000 in 5% milk TBS-T. Following overnight 
incubation with primary antibodies at 4°C, the membranes were washed three 
times in PBS-T or TBS-T and then incubated with the secondary antibody at 
room temperature for 1 hour. The concentration of secondary antibody used was: 
Goat anti-mouse IgG20-HRP – 1:1000. Images were acquired using the ECL 
machine and the signal density of each band was measured using ImageJ. In 
each lane, the signal density of the PGC-1α band was normalized to the 
associated α-tubulin band signal density. Then, the ZLN005 α-tubulin normalized 
PGC-1α signal densities were normalized to that of the vehicle.  
 
Quantification of mitochondria superoxide production  
Prior to 24-hour treatment with 10µM ZLN005 or vehicle, the cells were 
serum starved for 24 hours. The vehicle and 10µM ZLN005 were prepared in 
serum free DMEM/F12. After treatment, cells were washed with Hanks Buffered 
Salt Solution (HBSS, Thermo Fisher) and removed from the adherent surface 
using Trypsin-EDTA. Cells were re-suspended at a concentration of 300,000 
cells in 1.8 ml of 5µM MitoSox Red mitochondrial superoxide indicator (Thermo 
Fisher) in HBSS and incubated at 37°C, 5% CO2 for 30 minutes. The suspended 
cells are plated in a 96-well plate and the associated fluorescence was measured 




Cell Death Assay 
Quiescent ARPE-19 cells were grown to confluency in growth medium and 
then maintained for 24 hours in serum free DMEM/F12. Differentiated cells were 
kept in serum free conditions after one week in differentiation medium. Cells 
were pre-treated with 10µM ZLN005 prepared in serum free, phenol free DMEM 
for 24 hours before treatment with 500-1000µM hydrogen peroxide (H2O2) or 2 - 
3 mg/ml sodium iodate (NaIO3). After 18 and 24 hours of pro-oxidant exposure 
respectively, the supernatant media was collected and centrifuged to remove 
cells and debris. Cell death was quantified by the release of lactate 
dehydrogenase (LDH) from the cytoplasm of damaged cells into the media using 
the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega Corp, Madison, 
WI, USA) which quantifies LDH levels as an optical density (OD) at 490nm. 
Background levels of LDH present in the medium alone were measured, 
averaged and subtracted from all other samples. Basal levels of LDH (0% cell 
death), measured in the supernatant of vehicle only treated cells, and maximal 
levels of LDH (100% cell death, total kill), measured by inducing complete cell 
death with 1x Lysis Buffer, were averaged and used to calculate percentage cell 









 All in-vivo experimental procedures were approved by the Schepens Eye 
Research institutional animal care and use committee. Eight-week old male 
C57BL/6J mice (Jackson Laboratory, Bar Harbour, ME) were housed in standard 
laboratory environment and maintained on a 12-hour light dark cycle at 21°C. 
Intravitreal injections of 20μM ZLN005/vehicle were performed on anesthetized 
animals in a 1μL volume using a 33-gauge needle. After 24 and 72 hours, mice 
were euthanized and the eyes were enucleated. RNA was extracted from the 
RPE/choroid and neural retina, and gene expression was analyzed through 
qPCR.  
 
Design of PGC-1β Tetracycline Inducible (Tet-On) Adenovirus 
To control the upregulation of PGC-1β, an all-in-one tetracycline inducible 
PGC-1β adenoviral vector was designed (Fig. 4). The plasmid contains the Tet-
On-3G gene that is transcribed and translated into a protein trans-activator. This 
trans-activator undergoes a conformational change in the presence of 
doxycycline (Dox) and activates the transcription of the TRE3G promoter.  This 
allows the transcription of the human PGC-1β gene, fused to the tag protein Myc 
for protein detection, and the enhanced green florescent protein (EGFP) gene to 
be tightly modulated by doxycycline concentration. An internal ribosome entry 
sequence (IRES) is inserted between the PGC-1β-Myc and EGFP sequences to 
allow for independent translation of the two proteins.  Before adenoviral 




to doxycycline. The plasmid and adenovirus were produced by Vector Builder 
(Vector Builder, Santa Clara, CA) using synthetic gene synthesis. 
 
Transfection of ARPE-19 cells with PGC-1β Tet-On plasmid 
 The PGC-1β Tet-On plasmid was created by Vector Builder. The plasmid 
was collected using the Qiagen Maxi-prep protocol (Qiagen, Valencia, CA, USA) 
and resuspended in Tris-EDTA buffer. The concentration and purity of the DNA 
was measured using the NanoDrop 2000 spectrophotometer (Thermo Fisher 
Scientific).  
 
Figure 4: PGC-1β Tetracycline Inducible (Tet-On) Plasmid. The plasmid has the 
Tet-On 3G transactivator gene that controls the transcription of PGC-1β, Myc and 
EGFP under the TRE3G promoter. Ampicillin Resistance (AmpR) is added to help 
select bacteria cells containing the plasmid. Ori is the origin of replication and the grey 




ARPE-19 cells were seeded at 25,000 cells/cm2 in a 24-well plate. At 70% 
confluency, ARPE-19 cells were transfected with 2μg of plasmid DNA using 4 μl 
of Optifect transfection reagent (Thermo Fisher Scientific) in OptiMEM media, 
containing reduced serum and no antibiotics (Thermo Fisher Scientific), for 24 
hours. Doxycycline (Sigma) concentrations of 0.01μg/ml, 1μg/ml and 100μg/ml 
were prepared in serum free DMEM/F12 and added to the cells for 48 hours 
before RNA extraction. For LDH quantification, cells were seeded at 15,000 
cells/cm2 in a 48-well plate. Transfection was carried out as described above and 
cells were exposed to 0.01μg/ml Dox, prepared in serum free DMEM/F12, for 48-
hours before 24-hour treatment with 10μM ZLN005/veh in phenol free DMEM. 




Statistical analysis was carried out by GraphPad Prism 5 software (GraphPad 
Software Inc., La Jolla, CA). Data is presented in graphs as mean ± SEM. The 
Student’s t-test or the two-way ANOVA followed by Tukey’s multiple comparison 
test was used to calculate statistical significance. Statistical significance is 
denoted by the following: ns P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001, **** 






ZLN005 upregulates PGC-1α and its associated targets in ARPE-19 cells 
ZLN005 upregulates PGC-1α in skeletal muscle myotubes, but not in 
hepatocytes (Zhang et al. 2013). Because ZLN005’s action appears cell-specific, 
the effect of ZLN005 on ARPE-19 cells was investigated in both quiescent and 
differentiated cells. Endogenous PGC-1 expression in RPE is indeed tightly 
regulated by the cell epithelialization status and our lab has previously shown 
that PGC-1α is induced in ARPE-19 cells only after differentiation for one week 
(Iacovelli et al. 2016).  
First, qPCR analysis was used to investigate whether ZLN005 was able to 
upregulate PGC-1 isoforms and their main targets in the quiescent ARPE-19 
monolayer, which has low basal expression of PGC-1α. Total RNA was collected 
from cells that were treated for 48 hours with 10µM ZLN005 or vehicle. 
Treatment with ZLN005 increased the expression of PGC-1α (p < 0.0001), PGC-
1β (p < 0.0001), SOD2 (p = 0.0001), and ATP50 (p < 0.0001) compared to the 
vehicle (Fig. 5A, 5B). These results confirmed that ZLN005 increases gene 
expression of PGC-1 isoforms in RPE and potentially promotes RPE anti-oxidant 
activity through the upregulation of SOD2, the mitochondrial superoxide 
dismutase. ZLN005 may also affect oxidative phosphorylation through the 
upregulation of ATP50, a component of the mitochondrial ATPase involved in the 
ETC. ZLN005’s impact on mitochondrial function was examined by measuring 




treatment with ZLN005 decreases mitochondrial superoxide production, a major 
source of intracellular ROS (Fig. 5C).   
 Second, to examine if ZLN005 could upregulate PGC-1α in cells already 
expressing high basal levels, differentiated cells were treated with ZLN005. An 
increase in PGC-1α (p < 0.0001), PGC-1β (p < 0.0001), FOX03 (p = 0.0004), 
ESRRA (p = 0.04) and NRF2 (p = 0.01) expression was observed above the 
vehicle control (Fig. 5D). Mitochondrial respiration gene, ATP50 (p = 0.0007), 
and mitochondrial dynamic gene, FIS1 (p < 0.0001) were also upregulated with 
ZLN005 treatment (Fig. 5E). While ATP50 was also induced in the ARPE-19 
monolayer, the impact on mitochondrial dynamic gene, FIS1 was not observed, 
potentially due to low basal mitochondrial dynamic gene expression in the 
quiescent monolayer (Iacovelli et al. 2016). Although ZLN005 was able to 
increase the expression of key anti-oxidant transcription factors, a significant 
increase in SOD2 was not observed. However, the decrease in mitochondrial 
superoxide production was maintained in differentiated cells treated for 24 hours 






Figure 5: ZLN005 upregulates PGC-1α in ARPE-19 cells (A) Relative gene 
expression (RE) of anti-oxidant transcription factors in ARPE-19 monolayer treated 
for 48-hours with ZLN005 compared to vehicle (veh). ZLN005 causes the 
upregulation of PGC-1α and PGC-1β (n = 4 for each gene). (B) ZLN005 upregulates 
expression of anti-oxidant enzyme, SOD2 and mitochondrial ETC enzyme, ATP50 (n 
= 3 for each gene). (C) Mitochondrial (Mt) superoxide production is measured as fold 
change to veh. ZLN005 decreases superoxide production in the ARPE-19 monolayer 
(n = 5 for both conditions). (D) Differentiated cells treated with ZLN005 for 48 hours 
upregulate expression of PGC-1α, PGC-1β, FOX03, ESRRA and NRF2 (n = 4 for 
each gene). (E) ZLN005 upregulates ATP50 and mitochondrial gene, FIS1 in 
differentiated cells (n = 4 for each gene). (F) Mitochondrial superoxide production is 
decreased in the differentiated ARPE-19 after 24-hour treatment with ZLN005 (n = 4 
for veh, n = 5 for ZLN005). (G) Western blot of PGC-1α and α-tubulin protein bands 
from the ARPE-19 monolayer treated with veh/ZLN005. (H) Western blot 
quantification where the α-tubulin normalized signal density of ZLN005 PGC-1α 
bands is normalized to the veh PGC-1α bands (n = 3 for both conditions). All gene 
expression data was analyzed by two-way ANOVA followed by Tukey's multiple 
comparison test. Mitochondrial superoxide production was analyzed using the 
Student’s T-test. Statistical significance is represented as follows: * P < 0.05, ** P < 
0.01, *** P < 0.001, **** P < 0.0001. 
 
  








































































































































 The impact of ZLN005 on PGC-1α expression at the protein level was 
examined by Western blot analysis of protein lysates from the ARPE-19 
monolayer. An increase in protein levels was observed with 48-hours of ZLN005 
treatment compared to the vehicle control (Fig. 5G). To quantify the western blot, 
the PGC-1α signal densities were first normalized to the corresponding α-tubulin 
signal densities. Then, the α-tubulin normalized PGC-1α ZLN005 signal densities 
were normalized to that of the vehicle control (Fig. 5H). The increase observed in 
the western blot was found to be non-significant, using a Student’s T-test, due to 
the low number of replicates and further work will focus on reproducing these 
results.  
 
ZLN005 anti-oxidant effect on RPE is PGC-1α-dependent  
ZLN005 treatment upregulates key anti-oxidant transcription factors and 
decreases ROS levels in ARPE-19 cells, potentially creating an environment for 
these cells to withstand oxidative stress. To determine if ZLN005 was able to 
protect cells in pro-oxidative conditions, ARPE-19 cells were exposed to 
hydrogen peroxide (H2O2) and sodium iodate (NaIO3). Hydrogen Peroxide is a 
form of ROS that is produced endogenously in RPE during respiration and 
phagocytosis of POS (Miceli, Liles, and Newsome 1994). ARPE-19 cells pre-
treated for 24 hours with 10µM ZLN005 or vehicle were exposed to 500µM or 
1000µM H2O2 for 18 hours. To measure cell death, lactate dehydrogenase (LDH) 
released from the cytoplasm of apoptotic or necrotic cells was quantified as an 




decrease in cell death (Fig. 6A and 6B) caused by 500µM (monolayer: p = 0.02, 
differentiated: p = 0.002) and 1000µM H2O2 (monolayer: p = 0.0001, 
differentiated: p<0.0001). To determine if ZLN005’s protection against oxidative 
stress is dependent on PGC-1α, ARPE-19 cells silenced for PGC-1α (shPGC-1α) 
and the associated control (shControl), previously generated by the laboratory 
and provided by Dr. Rosales (Saint-Geniez lab, Schepens Eye Research 
Institute), were exposed to 1000µM H2O2. As expected, ZLN005 is no longer able 
to protect shPGC-1α cells (p = 0.34) from H2O2 mediated cytotoxicity, but 
decreased cell death in the shControl cells (p < 0.0001) (Fig. 6C). This indicates 
that PGC-1α is required for ZLN005 anti-oxidant function.  
While the exogenous addition of H2O2 is commonly used to induce 
oxidative stress on cultured cells, it does not accurately mimic the RPE 
dysfunction caused in AMD. Therefore, the effect of ZLN005 on cell death 
induced by sodium iodate, a stable oxidant that is used in animal models 
(Redfern et al. 2011; Franco et al. 2009) and cell culture (Wang et al. 2014) to 
cause retinal degeneration and RPE dysfunction similar to that in geographic 
atrophy in AMD patients, was examined. Pre-treatment with ZLN005 protects 
both the ARPE-19 monolayer (2mg/ml: p = 0.0009, 2.5mg/ml: p = 0.0002, 
3mg/ml: p<0.0001) and differentiated cells (p<0.0001 for all concentrations) from 
NaIO3-mediated cytotoxicity (Fig. 6D and 6E). With differentiated ARPE-19 cells, 
pre-treatment with ZLN005 decreased LDH levels below basal levels, measured 




additional anti-oxidant transcription factors in differentiated cells with ZLN005 
treatment (Fig. 5). 
OD490nm measured from cells treated with vehicle (p = 0.90) or ZLN005 (p 
= 0.74) alone for 48 hours were not significant compared to untreated ARPE-19 
cells not exposed to any additives. Therefore, treatment with vehicle or ZLN005 
Figure 6: ZLN005 protects ARPE-19 cells from pro-oxidant induced cell death 
through the upregulation of PGC-1α. Cell death induced by 18-hour exposure to 
500μM and 1000μM H2O2 decreases significantly with pre-treatment with 10μM 
ZLN005 in the (A) ARPE-19 monolayer (n = 6 for all conditions) and (B) Differentiated 
ARPE-19 (n = 6 for all conditions). (C) Cells lacking PGC-1α (shPGC-1α) show a loss 
of the protective effect of 10μM ZLN005 upon exposure to 1000μM H2O2 (n=6), while 
the effect is maintained in the associated control cells (shControl) (n=12). 24-hour 
pre-treatment with 10μM ZLN005 protects against NaIO3 induced cell death in (D) the 
quiescent ARPE-19 monolayer (n = 6 for all conditions) and (E) Differentiated ARPE-
19. Pre-treatment with ZLN005 in differentiated cells decreased LDH levels below 
basal LDH levels when exposed to 2 and 2.5mg/ml NaIO3 (n = 5 for veh, n = 6 for 
ZLN005) (F) 48-hours of exposure to ZLN005 (n = 6) does not increase LDH levels, 
measured as OD490, compared to untreated cells (UNT, n = 6) and vehicle only 
treatment (veh, n = 6). Total Kill (TK) of cells is achieved by treatment with 1x Lysis 
Buffer for 30 min. All data sets were analyzed using the Student’s T-test (ns P > 0.05, 































































































alone was not cytotoxic (Fig. 6F). The OD490nm of cells exposed to total kill (TK) 
conditions was significant when compared to the untreated, vehicle and ZLN005 
conditions (p<0.0001).   
 
ZLN005 increases expression of certain anti-oxidants in the neural retina 
 Due to the effectiveness of ZLN005 in protecting ARPE-19 cells from 
oxidative stress, ZLN005 was administered to mice through intravitreal injections. 
At 20µM, ZLN005 was deemed safe as it caused no cataract or damage to the 
ocular tissue. After 24 and 72 hours, the animals were euthanized and the neural 
retina and RPE were extracted from the eyes. Total RNA was extracted and 
gene expression of PGC-1 isoforms and their downstream targets were 
measured.  
 The neural retina expresses high levels of PGC-1β basally. While a slight 
increase in PGC-1β was observed 72 hours after the injection, this change was 
found to be nonsignificant (Fig. 7A). Anti-oxidants, GPX1 (p = 0.0285) and TXN2 
(p = 0.0442), and ETC gene, ATP50 (p = 0.0058) were upregulated by ZLN005 
treatment 72 hours after injection (Fig. 7B), while expression of anti-oxidant 
transcription factor FOXO3 (p = 0.0112) decreased (Fig. 7C). No significant 
change in ESRRA and NRF1 expression was observed.  
 In the RPE, no change in PGC-1α expression was observed. PGC-1β 
levels moderately decreased 24 hours after treatment and slightly increased 72 




in expression 24 hours after treatment (Fig. 7E). All these changes in the 
RPE/choroid layers were found to be non-significant. No change in ESRRA, 
GPX1 and TXN2 expression was observed (Fig. 7F).  
 
Evaluation of a novel doxycycline dependent PGC-1β expression vector 
system 
 The tetracycline inducible PGC-1β adenovirus plasmid (Fig. 4) was 
designed to modulate the level of PGC-1β upregulation in cell culture in order to 
mimic the induction levels observed in AMD patients.  
Figure 7: ZLN005 increases expression of anti-oxidants in the neural retina. (A) 
Gene expression of PGC-1 isoforms in the neural retina at 24 (n = 4 for all conditions) 
and 72 hours (n = 4 for veh, n = 3 for ZLN005) after treatment (B) Anti-oxidants GPX1 
and TXN2 had a significant increase in expression in the neural retina 72 hours after 
treatment. ETC gene, ATP50, was also upregulated. (C) FOX03 expression 
significantly decreased 72 hours after treatment (D) PGC-1 isoform expression in the 
RPE at 24 (n = 4 for all conditions) and 72 hours (n = 4 for veh, n = 3 for ZLN005) 
after ZLN005 was administered. (B) Slight upregulation in FOX03, NRF1 and ATP50 
was observed 24 hours after treatment in the RPE. (C) No change in ESRRA, GPX1 
and TXN2 was observed in the RPE. All data sets were analyzed using two-way 
ANOVA followed by Tukey's multiple comparison test (* P < 0.05, ** P < 0.01, *** P < 













































































































To test the sensitivity of the tetracycline inducible system to doxycycline 
induction prior to adenoviral production, the plasmid was isolated and transfected 
into ARPE-19 cells. PGC-1β expression (Fig. 8A) was increased in the presence 
of 0.01 µg/ml (p = 0.0012) and 100 µg/ml (p = 0.0261) doxycycline compared to 
transfected cells not exposed to doxycycline. There was a significant rise in 
PGC-1β expression with 100 µg/ml compared with 0.01 µg/ml (p = 0.03). EGFP 
expression (Fig. 8B) was also increased with 0.01 µg/ml Dox (p = 0.0024).  An 
increase was observed with 100 µg/ml doxycycline however this increase was 
non-significant due to high variability between the data points.  
 
Figure 8: PGC-1β expression is sensitive to doxycycline concentration. (A)  
Induction of PGC-1β expression with different concentration of doxycycline (n = 2 per 
group).  (B) EGFP expression induced by doxycycline addition (n = 2 per group). (A)-
(B) Data was analyzed using the Student’s T-test (* P < 0.05, ** P < 0.01, *** P < 
0.001 compared to 0 µg/ml Dox, # P< 0.05 compared to 0.01 µg/ml ) (C) Expression 
of downstream targets of PGC-1β in un-transfected cells (Unt, n = 3), transfected cells 
exposed to no doxycycline (Dox-, n = 3), and transfected cells treated with 1 µg/ml 
doxycycline (Dox+, n = 3) for 48-hours. Data was analyzed using two-way ANOVA 
followed by Tukey's multiple comparison test (* P < 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001 compared to Dox-, ### P< 0.001, #### < 0.0001 compared to Unt) 
(D) 1000µM H2O2-mediated cell death increases in cells treated with 0.01 µg/ml 
doxycycline (n = 6) for 48 hours compared to transfected cells not exposed to 
doxycycline (n = 3). ZLN005 protects cells in both conditions (n = 3 for Dox-, n = 6 for 
Dox+) from cell death. Data was analyzed using two-way ANOVA followed by Tukey's 
multiple comparison test (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 






























































































To measure the expression of downstream targets of PGC-1β, 1 µg/ml 
Dox was added to transfected cells for 48 hours (Fig. 8C). Gene expression of 
un-transfected cells and transfected cells treated with doxycycline (Dox+) was 
normalized to that of transfected cells not exposed to doxycycline (Dox-). Un-
transfected cells were found to have a significant reduction in PGC-1β (p = 
0.0024), ESRRA (p = 0.04), SOD2 (p = 0.03) and NRF2 (p = 0.045), and an 
increase in PGC-1α (p = 0.02) expression when compared to the Dox- cells. This 
unexpected induction of PGC-1β (Fig. 8C) in Dox- cells is potentially due to 
vector leakiness or the presence of tetracycline in the cell media and further 
evaluations are on-going. As expected, no basal expression of EGFP (p = 
0.0082) was measured in un-transfected cells.  
Doxycycline addition upregulated PGC-1β 4-fold (p < 0.0001) and EGFP 
2-fold (p < 0.0001) above the Dox- control. Dox+ cells were found to have 
increased expression of ESRRA (p < 0.0001) and SOD2 (p < 0.0001). When 
compared to un-transfected cells, Dox+ cells upregulated PGC-1β (p < 0.0001), 
EGFP (p < 0.0001), ESRRA (p < 0.0001), SOD2 (p < 0.0001), FOXO3 (p = 
0.0006) and NRF2 (p = 0.0002).  
 Dox+ cells were found to have significantly higher expression of 
transcription factor, ESRRA, and anti-oxidant enzyme, SOD2. To examine if this 
upregulation conferred protection to Dox+ cells upon exposure to oxidative 
stress, Dox-  and Dox+ cells were treated with 1000µM H2O2 with or without pre-




Dox, which caused a 2-fold rise in PGC-1β expression (Fig. 8A). Dox+ cells 
experienced more cell death in the presence of 1000µM H2O2 compared to Dox- 
cells (p = 0.009), indicating that a 2-fold induction of PGC-1β makes cells more 
susceptible to oxidative stress. ZLN005 was able to protect both Dox- (p = 0.009) 



















The purpose of this study was to evaluate the role of PGC-1 isoforms in 
RPE metabolism through two specific aims. Through Aim 1, compound ZLN005 
was found to effectively upregulate the PGC-1 isoforms and confer protection 
against oxidative stress in the ARPE-19 cell line. In Aim 2, a novel vector for 
doxycycline dependent PGC-1β induction was designed and validated.  
 In Aim 1, treatment with 10 µM ZLN005 was found to effectively 
upregulate gene expression of both PGC-1 isoforms and their associated targets 
in the ARPE-19 cell line. However, this induction was dependent on whether cells 
were quiescent or differentiated, as not all downstream targets of the isoforms 
were found to be upregulated in all conditions. For instance, SOD2 was only 
found to be induced in quiescent cells while ESRRA, NRF2 and FOXO3 were 
upregulated in differentiated cells. This selective induction could point to specific 
pathways activated by ZLN005 treatment in response to the cell metabolic and/or 
redox status. Differentiation could be a factor that can change the oxidative 
status of cells, as quiescent cells are transitioning from glycolytic to oxidative 
metabolism and oxidative phosphorylation is a major source of endogenous ROS 
in differentiated cells (Iacovelli et al. 2016, Agathocleous et al., 2012). Despite 
the potentially different mechanisms utilized in quiescent and differentiated cells, 
ZLN005 decreased mitochondrial superoxide production in both conditions. 
Furthermore, protein expression of ARPE-19 monolayer lysate showed an 




number of repeats. Future work will focus on repeating these experiments and 
quantifying upstream and downstream target protein expression.  
ZLN005 also provided protection against H2O2 and NaIO3 mediated 
cytotoxicity. Interestingly, differentiated cells exposed to NaIO3 showed a 
decrease in LDH levels below basal levels, leading to a negative percentage cell 
death. This phenomenon was not observed in the quiescent ARPE-19 monolayer 
exposed to NaIO3 and could be indicative of the different mechanisms utilized by 
ZLN005 as mentioned above.  By testing the effect of ZLN005 in PGC-1α 
silenced cells, it was determined that PGC-1α plays an integral role in mediating 
the cytoprotective effect of ZLN005. However, PGC-1α is not the only PGC-1 
isoform upregulated. PGC-1β, which is normally repressed in ARPE-19, is also 
induced with ZLN005 treatment. Through previous work done by our group, 
PGC-1β upregulation was found to increase H2O2 mediated cell death (Charles 
and Saint-Geniez 2017). Despite inducing PGC-1β, ZLN005 is able to protect 
cells from H2O2 induced oxidative damage and has no basal cytotoxic effect on 
ARPE-19 cells. This suggests that the ratio of PGC-1α : PGC-1β expression 
plays an important role in RPE function and this observation is supported by the 
cellular dysfunction observed when this ratio is decreased. To elucidate the role 
PGC-1β expression plays in ZLN005 anti-oxidant function, the effect of ZLN005 
on oxidative stress should be tested in PGC-1β silenced cells.  
Intravitreal injections of ZLN005 was not found to have significant effect on 




As a small sample size of animals were used for this study, further work will 
involve measuring the effect of higher ZLN005 concentrations in a larger sample 
size of animals. It is important to note that the intravitreal injection of ZLN005 did 
not cause any obvious deleterious changes to the structure of the eye or toxic 
responses within the animals. Histological sectioning of the eye will be performed 
to confirm that ZLN005 does not cause structural changes in the retinal and RPE 
layers. As ZLN005 action may be dependent on the oxidative environment of the 
cells, future work will involve testing an appropriate ZLN005 concentration on a 
mouse model of RPE dysfunction. While further work is needed, this current 
study has introduced ZLN005 as a potential therapeutic against AMD 
pathogenesis.  
Aim 2 of this study focused on designing a novel vector for doxycycline 
dependent PGC-1β induction. The effect of increasing doxycycline concentration 
on PGC-1β expression was demonstrated in ARPE-19 cells transfected with the 
vector. With 1µg/ml doxycycline, PGC-1β levels were upregulated 4 –times 
above the induction in transfected cells not treated with doxycycline, mirroring the 
fold changes observed in patients with choroidal neovascularization. Expression 
of downstream targets, ESRRA and SOD2, was increased with PGC-1β 
expression and is consistent with previous studies from our group (Charles and 
Saint-Geniez 2017). The work done in this study with transfected ARPE-19 cells 
has demonstrated the successful design of a doxycycline dependent PGC-1β 




the ARPE-19 cell line is not able to be easily transfected and is modified upon 
transfection. The increased efficiency and decreased stress of adenoviral 
delivery will allow for a well-modulated induction of PGC-1β in response to 
doxycycline concentration.  
Despite challenges faced during transfection, this modulated increase in 
PGC-1β expression was found to increase pro-oxidant induced cell death. This 
rise in cell death is seen with a 2-fold increase in PGC-1β expression and models 
the rise seen in CNV patients. Most importantly, ZLN005 was found to protect 
cells with increased PGC-1β expression against pro-oxidant mediated cell death. 
This demonstrates that ZLN005’s protective effect is maintained in cells with 
upregulated PGC-1β expression which suggests that this compound could be 
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